Monoclonal immunoglobulin preparations or pharmaceuticals with binding-avidity for HER2/neu (e.g. anti-HER2/neu: trastuzumab, pertuzumab) [1-5], EGFR (e.g. anti-EGFR: cetuximab, gefitinib) [6-9], immunoglobulin fractions with dual binding-avidity for both HER2/neu and EGFR (e.g. anti-HER2/neu and anti-EGFR properties: panitumumab) [8-11] or monoclonal immunoglobulin inhibitors of other trophic receptors can all be effective treatment options for cancer including forms of neoplasia affecting the breast, intestinal tract, lung and prostate. This evidence concerns the gene EGFR and cancer.